Evidence map›Paper›PMID 34396339›Full record

ArticleJACC. CardioOncology2021

Left Ventricular Assist Devices in Patients With Active Malignancies.

Ilana Schlam, Andy Y Lee, Song Li, Farooq H Sheikh, Raja Zaghlol, Binaya Basyal, Christopher Gallagher, Ezequiel Molina, Claudius Mahr, Richard K Cheng and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JACC. CardioOncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
0.9field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Mechanical circulatory support as a bridge to cancer therapy in patients with end stage heart failure: a single center experience.Journal of artificial organs : the official journal of the Japanese Society for Artificial Organs · 2026
    Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Novel Therapeutics for Anthracycline Induced Cardiotoxicity.Frontiers in cardiovascular medicine · 2022
    Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Ilana SchlamMedStar Washington Cancer Institute, Washington, DC, USA.
Andy Y LeeDepartment of Cardiology, University of Washington Medical Center, Department of Cardiology, Seattle, Washington, USA.
Song LiDepartment of Cardiology, University of Washington Medical Center, Department of Cardiology, Seattle, Washington, USA.
Farooq H SheikhMedStar Heart and Vascular Institute, Washington, DC, USA.
Raja ZaghlolInternal Medicine Department, MedStar Washington Hospital Center, Washington, DC, USA.
Binaya BasyalMedStar Heart and Vascular Institute, Washington, DC, USA.
Christopher GallagherMedStar Washington Cancer Institute, Washington, DC, USA.
Ezequiel MolinaMedStar Heart and Vascular Institute, Washington, DC, USA.
Claudius MahrDepartment of Cardiology, University of Washington Medical Center, Department of Cardiology, Seattle, Washington, USA.
Richard K ChengDepartment of Cardiology, University of Washington Medical Center, Department of Cardiology, Seattle, Washington, USA.
Ana BaracMedStar Heart and Vascular Institute, Washington, DC, USA.
MedStar Washington Hospital Center · USUniversity of Washington Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThere are limited data to guide oncology and cardiology decision-making in patients with a left ventricular assist device (LVAD) and concurrent active malignancy.

objectivesThe goal of this study was to describe cancer treatment approaches, complications, and survival among patients with active cancer on LVAD support in 2 tertiary heart failure and oncology programs.

methodsIn this retrospective cohort study, LVAD databases were reviewed to identify patients with a cancer diagnosis at the time of or after LVAD implantation. We created a 3:1 matched cohort based on age, sex, etiology of cardiomyopathy, LVAD implant strategy, and INTERMACS profile stratified by site. Kaplan-Meier analysis and Cox proportional hazards models were used to compare survival between patients with cancer and non-cancer comparators.

resultsAmong 1,123 patients who underwent LVAD implantation between 2005 and 2019, 22 patients with LVADs with active cancer and 66 matched non-cancer comparators were identified. Median age was 62 years (range 41 to 73 years); 50% of patients with cancer were African-American, and 27% were women. Prostate cancer, followed by renal cell cancer and hematologic malignancies were the most common diagnoses. There was no significant difference in unadjusted Kaplan-Meier median survival estimates from the time of LVAD placement between patients with cancer (3.53 years; 95% confidence interval [CI]: 1.41 to 5.33) and non-cancer comparators (3.03 years; 95% CI: 1.83 to 5.26; log-rank

conclusionsOur study provides initial feasibility and safety data and set a framework for multidisciplinary team management of patients with cancer and LVADs.

Indexed as

advanced heart failurecancercancer therapiesCI, confidence intervalCMP, cardiomyopathyCTCAE, common terminology criteria for adverse eventsCVD, cardiovascular diseaseDT, destination therapyGI, gastrointestinalHF, heart failureleft ventricular assist deviceLVAD, left ventricular assist device

Identifiers

PMID34396339
PMCPMC8352017
OpenAlexW3166529913

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.